Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 282

Sort by

Sort Order Select

Journal Articles

Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas

Blood (2023) 142 (22): 1871–1878.

https://doi.org/10.1182/blood.2023021187

Published: 2023

Includes: Supplemental data

Journal Articles

Unraveling Antioxidative Metabolic Pathways in Multiple Myeloma: Augmenting IMiD Sensitivity through Intracellular Cysteine Biosynthesis Inhibition

Sinto Sebastian Chirackal, Taro Hitosugi, Gregory Ahmann, Esteban Braggio, Marta Chesi, P. Leif Bergsagel, Rafael Fonseca

Blood (2023) 142 (Supplement 1): 3291.

https://doi.org/10.1182/blood-2023-189785

Published: 2023

Journal Articles

Real-World Treatment Outcomes of Teclistamab Under an Outpatient Model for Step-up Dosing Administration

Tyler B. Sandahl, Scott A. Soefje, Ediz S. Calay, Yi Lin, Rafael Fonseca, Sikander Ailawadhi, Ricardo Parrondo, Dee Lin, Bingcao Wu, Eli Silvert, Nina Kim, Corinne Carpenter, Tyler E. Wagner, Jessica Fowler, Laura Hester, Alexander Marshall, Patrick Stoy, Dina Gifkins, Shaji Kunnathu Kumar

Blood (2023) 142 (Supplement 1): 5154.

https://doi.org/10.1182/blood-2023-174270

Published: 2023

Journal Articles

Performance of Newer Staging Systems for Myeloma in a Contemporary, Large Cohort of Patients in the United States

Ghulam Rehman Mohyuddin, Samuel M Rubinstein, Shaji Kunnathu Kumar, S. Vincent Rajkumar, Rafael Fonseca, Nadine Abdallah, Greg Calip, Xiaoyan Wang, Christina Parrinello, Doug Sborov

Blood (2023) 142 (Supplement 1): 1068.

https://doi.org/10.1182/blood-2023-185136

Published: 2023

Journal Articles

Clinician Perspectives on Treatment-Decision in Triple-Class-Exposed Relapsed Refractory Multiple Myeloma in the United States: A Delphi-Based Research Study

Rafael Fonseca, Hoa H. Le, Nicole Lodowski, Amalia DeBrosse, Ian Daniel, Priyanka Narvekar, Xinke Zhang

Blood (2023) 142 (Supplement 1): 7400.

https://doi.org/10.1182/blood-2023-189083

Published: 2023

Journal Articles

Beyond the Primary: Unveiling the Prognostic Value of Secondary Cytogenetic Abnormalities in Multiple Myeloma

Rodrigo Fonseca, Mariano Arribas, Gregory Ahmann, Janna C Castro, Erin E Wiedmeier-Nutor, Linda Banovic Baughn, P. Leif Bergsagel, Rafael Fonseca

Blood (2023) 142 (Supplement 1): 2000.

https://doi.org/10.1182/blood-2023-190701

Published: 2023

Journal Articles

Early Predictors of Severe Cytopenia Post CAR-T for Identification of Patients for Potential Stem Cell Collection

Blood (2023) 142 (Supplement 1): 6927.

https://doi.org/10.1182/blood-2023-189683

Published: 2023

Journal Articles

Real-World Treatment Patterns and Clinical Outcomes Among Triple-Class Exposed and B-Cell Maturation Antigen (BCMA) Exposed Multiple Myeloma Patients

Hira Mian, Jennifer S. Harper, Hoa H. Le, Alex Z. Fu, Saurabh N. Patel, Xinke Zhang, Rafael Fonseca

Blood (2023) 142 (Supplement 1): 542.

https://doi.org/10.1182/blood-2023-189229

Published: 2023

Journal Articles

Comparison of the Efficacy in Clinical Trials Versus Effectiveness in the Real-World of Treatments for Multiple Myeloma: A Population-Based Cohort Study

Alissa Visram, Kelvin KW Chan, Hsien Seow, Gregory Pond, Ana Gayowsky, Arleigh McCurdy, Irwindeep Sandhu, Christopher P. Venner, Guido Lancman, Amaris Balitsky, Robert Bruins, Shaji Kunnathu Kumar, Rafael Fonseca, Hira Mian

Blood (2023) 142 (Supplement 1): 541.

https://doi.org/10.1182/blood-2023-189506

Published: 2023

Journal Articles

Gain1q in Myeloma Randomized Clinical Trials- How Is It Reported and How Does It Impact Outcomes: A Systematic Review

Karun Neupane, Gliceida Galarza Fortuna, Riyasha Dahal, Timothy M Schmidt, Rafael Fonseca, Doug Sborov, Meera Mohan, Hira Mian, Rajshekhar Chakraborty, Ghulam Rehman Mohyuddin

Blood (2023) 142 (Supplement 1): 3363.

https://doi.org/10.1182/blood-2023-180271

Published: 2023

Journal Articles

Comparison of Time to Next Treatment or Death between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) and Bortezomib, Lenalidomide, and Dexamethasone (VRd) in Transplant Ineligible Patients with Multiple Myeloma

Doris K. Hansen, Santosh Gautam, Marie-Hélène Lafeuille, Carmine Rossi, Bronwyn Moore, Anabelle Tardif-Samson, Philippe Thompson-Leduc, Alex Z. Fu, Annelore Cortoos, Shuchita Kaila, Rafael Fonseca

Blood (2023) 142 (Supplement 1): 543.

https://doi.org/10.1182/blood-2023-187233

Published: 2023

Journal Articles

Modified Staging System for Waldenström Macroglobulinemia (MSS-WM): A Multi-Institutional Externally Validated Prognostic Model for Active/Symptomatic Waldenström Macroglobulinemia

Blood (2023) 142 (Supplement 1): 3030.

https://doi.org/10.1182/blood-2023-179940

Published: 2023

Journal Articles

Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review

Rafael Fonseca, Diana Tran, Emily Rosta, Alyshia Laidlaw, Manvir Rai, Joana Duran, Eric M. Ammann

Blood (2022) 140 (Supplement 1): 5212–5213.

https://doi.org/10.1182/blood-2022-165569

Published: 2022

Journal Articles

Patients with Monoclonal Gammopathy Have a High Rate of Second Symptomatic COVID-19 Infection Even after a Prior COVID-19 Infection and Vaccination

Blood (2022) 140 (Supplement 1): 10017–10019.

https://doi.org/10.1182/blood-2022-167181

Published: 2022

Journal Articles

Causes of Death Among Patients with Multiple Myeloma: A 10 Year Longitudinal Analysis of a Population-Based Cohort in Ontario, Canada

Arleigh McCurdy, Hsien Seow, Gregory R Pond, Anastasia Gayowsky, Rajshekhar Chakraborty, Alissa Visram, Rayan Kaedbey, Anita D'Souza, Ghulam Rehman Mohyuddin, Rafael Fonseca, Hira S Mian

Blood (2022) 140 (Supplement 1): 427–429.

https://doi.org/10.1182/blood-2022-157815

Published: 2022

Journal Articles

Electrocardiogram As a Marker of Cardiac Response in Light Chain Amyloidosis

Rodrigo Fonseca, Yael Kusne, Mariano Arribas, Molly Klanderman, Julia E. Wiedmeier, Eli Muchtar, P. Leif Bergsagel, Craig B. Reeder, Jeremy T. Larsen, Rafael Fonseca, Julie L Rosenthal

Blood (2022) 140 (Supplement 1): 12566–12567.

https://doi.org/10.1182/blood-2022-168083

Published: 2022

Journal Articles

Pathogenic Germline Variants in a Prospective Multi-Center Cohort of Patients with Multiple Myeloma

Julia E. Wiedmeier, Michael A. Golafshar, Katie L. Kunze, Edward D. Esplin, Robert L. Nussbaum, A. Keith Stewart, Jewel Samadder, P. Leif Bergsagel, Rafael Fonseca

Blood (2022) 140 (Supplement 1): 7162–7163.

https://doi.org/10.1182/blood-2022-167940

Published: 2022

Journal Articles

LP-118, a Novel BCL2 Inhibitor, Shows Potent in Vitro Anti-Myeloma Activity

Rodrigo Fonseca, Yuan Xiao Zhu, P. Leif Bergsagel, Marta Chesi, Akhilesh Pandey, Kiran Mangalaparthi, Yi Chen, Felai Tan, Stephen P. Anthony, Yu Chen, Yue Shen, Bing Dai, Esteban Braggio, Rafael Fonseca

Blood (2022) 140 (Supplement 1): 7129–7130.

https://doi.org/10.1182/blood-2022-167372

Published: 2022

Journal Articles

Therapeutic Outcomes of Relapsed-Refractory Multiple Myeloma Patients with 1q21+Treated with Daratumumab-Based Regimens: A Retrospective Analysis

Ricardo D Parrondo, Lindsay Brooke Gardner, Mohamad Alhaj Moustafa, Vivek Roy, Taimur Sher, Ahsan Rasheed, Rahma M Warsame, Jeremy T. Larsen, Wilson I. Gonsalves, Taxiarchis Kourelis, Prashant Kapoor, Rafael Fonseca, Asher Chanan-Khan, Sikander Ailawadhi

Blood (2022) 140 (Supplement 1): 7237–7238.

https://doi.org/10.1182/blood-2022-169533

Published: 2022

Journal Articles

Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) +/- Daratumumab Treatment Results in Sustained Hematologic Response in Patients with AL Amyloidosis: A Retrospective Analysis of Patients at Mayo Clinic

Yael Kusne, Rodrigo Fonseca, Mariano Arribas, Molly Klanderman, Julia E. Wiedmeier, Craig B. Reeder, Jeremy T. Larsen, P. Leif Bergsagel, Julie L Rosenthal, Rafael Fonseca

Blood (2022) 140 (Supplement 1): 7224–7225.

https://doi.org/10.1182/blood-2022-166668

Published: 2022

NARROW

Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas

Unraveling Antioxidative Metabolic Pathways in Multiple Myeloma: Augmenting IMiD Sensitivity through Intracellular Cysteine Biosynthesis Inhibition

Real-World Treatment Outcomes of Teclistamab Under an Outpatient Model for Step-up Dosing Administration

Performance of Newer Staging Systems for Myeloma in a Contemporary, Large Cohort of Patients in the United States

Clinician Perspectives on Treatment-Decision in Triple-Class-Exposed Relapsed Refractory Multiple Myeloma in the United States: A Delphi-Based Research Study

Beyond the Primary: Unveiling the Prognostic Value of Secondary Cytogenetic Abnormalities in Multiple Myeloma

Early Predictors of Severe Cytopenia Post CAR-T for Identification of Patients for Potential Stem Cell Collection

Real-World Treatment Patterns and Clinical Outcomes Among Triple-Class Exposed and B-Cell Maturation Antigen (BCMA) Exposed Multiple Myeloma Patients

Comparison of the Efficacy in Clinical Trials Versus Effectiveness in the Real-World of Treatments for Multiple Myeloma: A Population-Based Cohort Study

Gain1q in Myeloma Randomized Clinical Trials- How Is It Reported and How Does It Impact Outcomes: A Systematic Review

Comparison of Time to Next Treatment or Death between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) and Bortezomib, Lenalidomide, and Dexamethasone (VRd) in Transplant Ineligible Patients with Multiple Myeloma

Modified Staging System for Waldenström Macroglobulinemia (MSS-WM): A Multi-Institutional Externally Validated Prognostic Model for Active/Symptomatic Waldenström Macroglobulinemia

Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review

Patients with Monoclonal Gammopathy Have a High Rate of Second Symptomatic COVID-19 Infection Even after a Prior COVID-19 Infection and Vaccination

Causes of Death Among Patients with Multiple Myeloma: A 10 Year Longitudinal Analysis of a Population-Based Cohort in Ontario, Canada

Electrocardiogram As a Marker of Cardiac Response in Light Chain Amyloidosis

Pathogenic Germline Variants in a Prospective Multi-Center Cohort of Patients with Multiple Myeloma

LP-118, a Novel BCL2 Inhibitor, Shows Potent in Vitro Anti-Myeloma Activity

Therapeutic Outcomes of Relapsed-Refractory Multiple Myeloma Patients with 1q21+Treated with Daratumumab-Based Regimens: A Retrospective Analysis

Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) +/- Daratumumab Treatment Results in Sustained Hematologic Response in Patients with AL Amyloidosis: A Retrospective Analysis of Patients at Mayo Clinic

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only